Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Last Hour:
Last 24 Hours:

Catalyst Pharma reports positive trial data for a treatment of a rare neuromuscular disease

Wednesday, March 15, 2017 7:09
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) saw its shares jump 20% in pre-market trading today after the biotech firm reported positive data from a trial of a treatment for a form of myasthenia gravis.

The Nasdaq-listed company said the investigator-sponsored trial of its Firdapse drug as a treatment for seven myasthenia gravis patients with anti-MuSK antibodies met its main goals.

The study of patents with the rare neuromuscular disease, for which there is currently no treatment, was conducted in Milan, Italy.

In a statement, Dr Renato Mantegassa, director of the department of neuroimmunology and neuromuscular diseases at the Fondazione Istituto Neurologico Carlo Besta said: “Not only are the results statistically significant, but more importantly, there was a large clinical benefit to the patients.”

Catalyst shares, which have gained 11% so far this year, were up 19.6% at US$1.40.

Story by ProactiveInvestors


Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.